Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.35 |
| ▸ | CBFB | Q13951 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | FLT1 | P17948 | 1/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CCL2 | P13500 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17197091 | 0.95 | GPBAR1 (0.37) | TAAR1SYKFFAR1GPBAR1NR4A2 | |
| SCHEMBL4677635 | 0.89 | KDR (0.37) | TAAR1SYKFFAR1KDRFGFR1 | |
| SCHEMBL16562822 | 0.83 | TAAR1 (0.40) | TAAR1DHODH | |
| SCHEMBL4678667 | 0.83 | LTA4H (0.39) | TAAR1 | |
| SCHEMBL19312814 | 0.81 | TAAR1 (0.39) | TAAR1SYKFFAR1KDRGPBAR1 | |
| SCHEMBL4680955 | 0.81 | LTA4H (0.42) | FFAR1 | |
| SCHEMBL14853644 | 0.81 | TAAR1 (0.39) | TAAR1SYKFFAR1KDRGPBAR1 | |
| SCHEMBL4682530 | 0.80 | SLC6A4 (0.39) | TAAR1FFAR1KDRKDM4E | |
| SCHEMBL7094266 | 0.80 | PLA2G2A (0.47) | — | |
| SCHEMBL17347650 | 0.79 | TAAR1 (0.32) | TAAR1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10350206-B2 | Benzyl substituted indazoles as BUB1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-07-16 | — | — | US | disclosed |
| US-10350206-B2 | Benzyl substituted indazoles as BUB1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-07-16 | — | — | US | disclosed |
| US-10266548-B2 | Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-04-23 | — | — | US | disclosed |
| US-20170333398-A1 | HETEROCYCLIC DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-11-23 | — | — | US | disclosed |
| US-20170305882-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-26 | — | — | US | disclosed |
| US-20170305882-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-26 | — | — | US | disclosed |
| US-20170273980-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | US | disclosed |
| US-20170273980-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | US | disclosed |
| US-20170275270-A1 | BENZYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | US | disclosed |
| US-20170275270-A1 | BENZYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | US | disclosed |
| WO-2016041925-A1 | BENZYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-24 | — | — | WO | disclosed |
| US-9265763-B2 | — | — | 2016-02-23 | — | — | US | disclosed |
| US-9265763-B2 | — | — | 2016-02-23 | — | — | US | disclosed |
| US-20140249133-A1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-04 | — | — | US | disclosed |
| US-20140249133-A1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-04 | — | — | US | disclosed |
| WO-2013050438-A1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES. | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-04-11 | — | — | WO | disclosed |
| EP-1343775-B1 | PIPERAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-06-04 | — | — | EP | disclosed |
| EP-1343775-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-17 | — | — | EP | disclosed |
| US-20020143020-A1 | Novel piperazine derivatives | VERNALIS RESEARCH LIMITED (GB) | 2002-10-03 | — | — | US | disclosed |
| WO-2002048124-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143020-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | TAAR1 319/4885SYK 3196/4885FFAR1 195/4885 |
| US-20170275270-A1 | BENZYL SUBSTITUTED INDAZOLES | UGT2B7, CYP3A43, CYP3A7 | TAAR1 3771/4885SYK 1977/4885FFAR1 2063/4885 |
| US-10350206-B2 | Benzyl substituted indazoles as BUB1 inhibitors | BUB1, BUB1B, BUB3 | TAAR1 4103/4885SYK 3263/4885FFAR1 4597/4885 |
| US-20170333398-A1 | HETEROCYCLIC DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | PRKAR2B, PRKAR2A, PRKAG3 | TAAR1 1528/4885SYK 958/4885FFAR1 29/4885 |
| US-20140249133-A1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BUB1, BUB1B, BUB3 | TAAR1 4327/4885SYK 2508/4885FFAR1 4363/4885 |
| US-20170273980-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 INHIBITORS | BUB1, BUB1B, BUB3 | TAAR1 4103/4885SYK 3263/4885FFAR1 4597/4885 |
| US-10266548-B2 | Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases | BUB1, BUB1B, BUB3 | TAAR1 4263/4885SYK 2434/4885FFAR1 4372/4885 |
| US-20170305882-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 KINASE INHIBITORS | BUB1, BUB1B, BUB3 | TAAR1 4123/4885SYK 2337/4885FFAR1 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.